Advanced Search


Study ID Status Title Patient Level Data
201020 Withdrawn A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the combination of Dabrafenib with Trametinib in Chinese Subjects with Melanoma
201021 Withdrawn A Phase I Study to Evaluate the Pharmacokinetics and Safety of Single and Repeat Oral Doses of Trametinib in Chinese Subjects with Solid Tumours
201022 Completed A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022 Study Listed on
201023 Terminated A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospitalized with influenza
201037 Completed A Single Centre, Open-label, 5-Period, Cross over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets Study Listed on
201038 Active, not recruiting Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study 201038)
201039 Completed A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers
201040 Completed A double blind, placebo-controlled first time in human study to evaluate the safety, tolerability and pharmacokinetics of single and repeat doses of GSK3036656 in healthy adult volunteers
201050 Relinquished Phase Ib study of afuresertib combined with paclitaxel in pre-treated HER2-negative advanced gastric cancer
201063 Relinquished PHoeBE - Patterns of care in HER2+ metastatic Breast cancer in Europe: A representative, retrospective study in Turkey
201065 Completed PGx7558: An Exploratory Study of Genetic Effects on Anoro (GSK573719/GW642444) in Chronic Obstructive Pulmonary Disease in Multiple Clinical Studies
201066 Completed PGx6712: An Exploratory Study of the Effects of 2 Common Variants in ADRB2 on Anoro (GSK573719/GW642444) Efficacy in Chronic Obstructive Pulmonary Disease in Multiple Clinical Studies
201067 Completed A prospective, non-interventional study of the use of dolutegravir as part of combination antiretroviral therapy in routine daily practice in Germany (DOL-ART)
201071 Completed An open-label study of the correct use and ease of use of placebo ELLIPTA dry powder inhaler in subjects with chronic obstructive pulmonary disease (COPD)
201072 Completed An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3206641A and GSK3206640A administered in adults 18 to 64 years of age Study Listed on
201076 Completed Seroprevalence of Hepatitis A, Hepatitis B and Bordetella pertussis in Mexico
201086 Withdrawn FluLaval® Quadrivalent Pregnancy Registry: a prospective, exploratory, cohort study to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with FluLaval® Quadrivalent during pregnancy or within 28 days preceding conception
201087 Active, Not Recruiting The burden of stage IB-IIIA non small cell lung cancer in Canada
201088 Relinquished Dabrafenib-Trametinib Combination Metastatic Melanoma Named Patient Programme Retrospective Chart Review (DESCRIBE II)
201092 Completed A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate from FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol from SERETIDE™ 250/25 HFA pMDI when given with the VENTOLIN Mini-Spacer Compared to the Aerochamber Plus Spacer in Healthy Subjects Study Listed on
201097 Recruiting The effectiveness of Asthma Control Test guided treatment compared with usual care in China adult asthma patients
201098 Recruiting Generation and Cognitive Testing of Informative and Suitable Items for a COPD Exacerbation Recognition Tool (CERT) for Detection of Exacerbations of COPD in Chinese Patients
201102 Completed A Phase 1, Open-Label, Crossover Study to Evaluate the Drug Interaction Between Dolutegravir and Daclatasvir in Healthy Adult Subjects
201108 Relinquished WEUKBRE7133: Drug Utilization Study (DUS) for REVOLADE™
201109 Terminated WEUSKOP7134: PASS HCV Research UK: Prospective observational cohort study to explore the safety and effectiveness of eltrombopag in a real-world setting in adult patients with chronic hepatitis C virus infection who are unable to initiate or maintain optimal interferon-based therapy due to thrombocytopenia nested within the HCV Research UK National Registry



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.